Treatment of complex regional pain syndrome using denosumab
View Patent ↗Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.
1. A method of treating pain comprising parenterally administering denosumab to relieve pain in a human being in need thereof, wherein the pain results from complex regional pain syndrome (CRPS).
2. The method of claim 1 , wherein the denosumab is administered subcutaneously.
3. The method of claim 2 , wherein about 120 mg of denosumab is administered to the human being over a four week period.
4. The method of claim 1 , wherein the denosumab is administered intravenously.
5. The method of claim 4 , wherein about 0.05 mg/kg to about 3 mg/kg of denosumab is administered to the human being over a four week period.
6. The method of claim 5 , wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the human being over a four week period.
7. The method of claim 6 , wherein about 30 mg to about 180 mg of denosumab is administered weekly to the human being for two to four weeks.
8. The method of claim 1 , wherein the denosumab is administered intramuscularly.
9. The method of claim 1 , wherein the denosumab is administered intradermally.
10. The method of claim 1 , wherein about 0.05 mg/kg to about 3 mg/kg of denosumab is administered to the human being over a four week period.
11. The method of claim 1 , wherein about 1 mg/kg to about 3 mg/kg of denosumab is administered to the human being over a three to five week period.
12. The method of claim 1 , wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the human being over a three to five week period.
13. The method of claim 1 , wherein about 1.1 mg/kg to about 2.5 mg/kg of denosumab is administered to the human being over a four week period.
14. The method of claim 1 , wherein about 30 mg to about 180 mg of denosumab is administered to the human being no more than once a week.
15. The method of claim 14 , wherein the human being experiences pain relief for at least 3 hours after administration of denosumab.
16. The method of claim 14 , wherein the human being experiences pain relief for at least 24 hours after administration of denosumab.
17. The method of claim 14 , wherein the human being experiences pain relief for at least one week after administration of denosumab.
18. The method of claim 1 , wherein about 100 mg to about 140 mg of denosumab is administered to the human being over a three to five week period.
19. The method of claim 1 , wherein about 120 mg of denosumab is administered to the human being over a four week period.
20. The method of claim 1 , wherein, within a period of about six months, about 0.1 mg/kg to about 20 mg/kg of denosumab is administered to the human being.
21. The method of claim 1 , wherein, within a period of about six months, about 0.5 mg/kg to about 2 mg/kg of denosumab is administered to the human being.
22. The method of claim 1 , wherein the human being experiences pain relief for at least 3 hours after administration of denosumab.
23. The method of claim 1 , wherein the human being is about 10 years old to about 90 years old.
24. The method of claim 1 , wherein denosumab is administered in at least two separate doses.
25. The method of claim 24 , wherein the second dose is administered at 5×T max or greater.
26. The method of claim 24 , wherein the second dose is administered within one year of the first dose.
27. The method of claim 1 , wherein denosumab is administered in a liquid composition comprising about 0.0001% (w/v) to about 50% (w/v) of denosumab.
28. The method of claim 1 , wherein about 5 mg to about 100 mg of denosumab is administered per dose.
29. The method of claim 28 , wherein denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent.
30. The method of claim 1 , wherein denosumab is administered in a pharmaceutical composition comprising a carrier, an excipient, a buffer, an antioxidant, or a diluent.